MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma

Inclusion Criteria:

- Advanced unresectable or metastatic melanoma, previously treated with ipilimumab;
anti-melanoma treatments, including anti-PD/PD-L1 or any other immunotherapy, are
allowed provided no treatment from last dose of that treatment to trial enrolment

- Subjects need to have

- one lesion that can be irradiated

- at least 1 measurable lesion outside the radiation field, different from the
lesion that will be irradiated

- one lesion that can be biopsied before treatment with SBRT and MSB0010445

- one lesion outside the radiation field that can be biopsied while on treatment
with MSB0010445

- The lesion that is biopsied at Baseline can be the lesion that will be irradiated

- The lesion that will be biopsied while on treatment should not be a lesion that has
been irradiated or biopsied at Baseline

- Signed written informed consent

- Male and female subjects at least 18 years of age

- Life expectancy greater than or equal to (>=) 4 months

- Eastern cooperative oncology group (ECOG) performance status of 0 or 1

- Other protocol defined inclusion criteria could apply

Exclusion Criteria:

- Active central nervous system metastasis

- Treatment with systemic anti-cancer therapy within the 30 days before the first dose
of SBRT

- Pre-existing pericardial effusion or history of Grade >=2 pleural effusion or ascites
within 3 months before first dose of SBRT

- Concurrent systemic therapy with steroids or other immunosuppressive agents except
short-term systemic steroids for allergic reactions

- Other protocol defined exclusion criteria could apply